Forecasting therapeutic responses by albuminuria and eGFR slope during the DAPA-CKD trial

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial is a landmark study that, along with a rapidly growing body of evidence, has firmly established SGLT2 inhibition as new standard of care for people with type 2 diabetes and chronic kidney disease. 1 Heerspink HJL Stefánsson BV Correa-Rotter R et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020; 383: 1436-1446 Crossref...